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Abstract
Background: Chronic neuroinflammation is an important component of Alzheimer’s disease and could contribute
to neuronal dysfunction, injury and loss that lead to disease progression. Multiple clinical studies implicate tumor
necrosis factor-α as an inflammatory mediator of neurodegeneration in patients with Alzheimer’s because of
elevated levels of this cytokine in the cerebrospinal fluid, hippocampus and cortex. Current Alzheimer’s disease
interventions are symptomatic treatments with limited efficacy that do not address etiology. Thus, a critical need
exists for novel treatments directed towards modifying the pathophysiology and progression.
Methods: To investigate the effect of early immune modulation on neuroinflammation and cognitive outcome, we
treated triple transgenic Alzheimer’s disease mice (harboring PS1M146V, APPSwe, and tauP301L transgenes) with the
small molecule tumor necrosis factor-α inhibitors, 3,6′-dithiothalidomide and thalidomide, beginning at four months
of age. At this young age, mice do not exhibit plaque or tau pathology but do show mild intraneuronal amyloid
beta protein staining and a robust increase in tumor necrosis factor-α. After 10 weeks of treatment, cognitive
performance was assessed using radial arm maze and neuroinflammation was assessed using biochemical,
stereological and flow cytometric endpoints.
Results: 3,6′-dithiothalidomide reduced tumor necrosis factor-α mRNA and protein levels in the brain and improved
working memory performance and the ratio of resting to reactive microglia in the hippocampus of triple transgenic
mice.
In comparison to non-transgenic controls, triple transgenic Alzheimer’s disease mice had increased total numbers of
infiltrating peripheral monomyelocytic/granulocytic leukocytes with enhanced intracytoplasmic tumor necrosis
factor-α, which was reduced after treatment with 3,6′-dithiothalidomide.
Conclusions: These results suggest that modulation of tumor necrosis factor-α with small molecule inhibitors is safe
and effective with potential for the long-term prevention and treatment of Alzheimer’s disease.
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Introduction
Tumor necrosis factor-α (TNFα) is a pleiotropic cytokine
originally recognized for its anti-tumor activity [1]. TNFα
plays a pivotal role in a wide variety of events mediated by
ligation and signaling through one of its cognate receptors,
TNF-RI or TNF-RII. In the central nervous system (CNS),
TNFα influences both developmental and pathophysio-
logical processes. These include promoting apoptosis during
neuronal target innervation [2], altering neurogenesis [3],
influencing cell fate determination [4], neuronal differ-
entiation [5] and neuronal morphology [6], augmenting
synaptic transmission [7-11] and induction and perpetu-
ation of the innate response during neurodegenerative
conditions such as multiple sclerosis, Parkinson’s disease
and Alzheimer’s disease (AD) (reviewed in [12]).
AD is a progressive neurodegenerative disease charac-
terized by neurotoxic beta amyloid protein (Aβ), neuritic
plaques, intraneuronal tau-containing neurofibrillary
tangles, synaptic degeneration, neuronal loss, inflamma-
tion and diminished cognitive function. Within the AD
neuritic plaque, Aβ peptides (Aβ1-40, Aβ1-42 and so on),
derived from amyloid precursor protein (APP), induce
inflammation and subsequent neuronal death [13,14].
Sustained, uncontrolled microglial cytokine production
drives neuroinflammation-induced AD neurodegenera-
tion [13,15-20]. Supporting this notion, multiple in vitro
studies reveal that Aβ-stimulated microglia induce syn-
aptic dysfunction and neuron death through an activated
cytokine network [19,21]. Activated microglia produce
several immune and inflammatory mediators (including
TNFα, IL-1, IL-6) that activate membrane receptor-
mediated intracellular processes in nearby neurons,
causing dysfunctional nerve signaling and, ultimately,
neuronal death [19,21]. Inflammatory mediators also
activate nearby microglia, establishing a chronic self-
propagating cycle of glial activation and neuronal death
[15,16,22]. This self-propagating cycle may underlie the
progressive accumulation of synaptic dysfunction and
neurodegeneration that leads to the observed cognitive
deficits in AD [13,15,16].
Clinical studies highlight the relevance of TNFα in AD.
Zhao et al. examined TNFα cascade components in vul-
nerable neuroanatomic locations of postmortem AD
brains, transitional cases diagnosed with mild cognitive
impairment (MCI) and cognitively unimpaired, age-
matched controls [23]. Cortical and hippocampal TNFα
levels were significantly elevated in patients with MCI
and with AD compared with age-matched controls.
Cerebrospinal fluid (CSF) and serum studies suggest
TNFα to be an early biomarker of MCI and AD progres-
sion [24,25]. TNFα levels in the CSF were 25-fold higher
in patients with AD compared to age-matched controls
[24-26] and MCI patients with high CSF TNFα levels
progress rapidly to AD [27]. Elevated CSF TNFα levels
correlate with clinical deterioration in patients with MCI
and with AD [26], suggesting that a rise in CSF TNFα
level precedes AD development.
Preclinical AD models demonstrate the deleterious role
of TNFα in AD-associated pathogenesis and cognitive
deficits. Mice receiving Aβ 1–40 by intracerebroventricu-
lar injection show marked deficits in learning and mem-
ory concomitant with elevated hippocampal TNFα
mRNA levels [28]. In several mouse models that recap-
itulate specific human AD-related pathologies, TNFα is
upregulated, co-localized with amyloid plaques, and is
neurotoxic. These include the Tg2576 [29], APPswe/
PS1dE9 [30] and 3 ×TgAD mouse models [31].
In the present study, we utilized the 3 ×TgAD mouse
model, which demonstrates age-dependent changes in
entorhinal cortex TNFα mRNA levels that strongly cor-
relate with learning and memory deficits. By 4 months
of age, TNFα mRNA levels are elevated 5.3-fold [31] and
at this age these mice display early memory retention
impairments [32]. Importantly, this TNFα elevation is
prior to the onset of overt extracellular amyloid or tau
pathology in 3 ×TgAD mice. At 6 months, entorhinal
cortex TNFα mRNA levels are 14.8-fold greater and
mice demonstrate significant deficits in spatial reference
learning. Starting from 4 months of age, 3 × TgAD mice
were treated with the small molecule TNFα inhibitor,
3,6′-dithiothalidomide (3,6′-DT), thalidomide (Thal) or
vehicle until they were 6.5 months of age. The mice were
subsequently tested for cognitive impairment using the
eight-arm radial arm maze (RAM) and the brains ana-
lyzed by immunohistochemical, biochemical and flow
cytometric techniques.
Methods
Cell culture: BV2 microglia and splenocytes
BV2 cells were maintained in culture medium (CM) con-
sisting of Dulbecco’s modified Eagle medium (DMEM+L-
Glutamine, ATCC Cat #30-2002; Manassas, VA, USA) with
10% FBS (ATCC Cat #30-2020), penicillin/streptomycin
(10,000 IU to 10,000 μg/mL; ATCC Cat#30-2300) in a 5%
CO2 incubator. Plated cells (30,000 cells/well; 96-well plate)
were grown in CM. In all experiments, cells were treated
with the indicated concentrations of 3,6′-DT, Thal or ve-
hicle (dimethyl sulfoxide; DMSO) in the absence or pres-
ence of lipopolysaccharide (LPS; 1 ng/mL; serotype O55:B5
from Escherichia coli) in serum-free CM. The final concen-
tration of DMSO was 1%. The media was collected at 24 h
after drug and LPS stimulation, briefly centrifuged to re-
move floating cells and debris and stored at −20°C prior to
ELISA analysis. Lactate dehydrogenase (LDH) assay (Pro-
mega CytoTox96 non-radioactive cytoxicity assay; Madison,
WI, USA) was performed in triplicate on CM as per manu-
facturer’s protocol.
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For analyses of spleen TNFα production, spleens from
Non-Tg and 3 ×Tg mice were mechanically dissociated
on a wire mesh by crushing with a 10 mL syringe, the
red blood cells depleted, and filtered through 70 μm
nylon strainers (BD Biosciences, San Diego, CA, USA).
Splenocytes (2.5 × 106 cells/mL) were cultured in CM in
triplicate for 24 h and TNFα secreted in the CM quanti-
fied by ELISA.
Animal studies
C57/Bl6 male mice were used for LPS injection studies
(same LPS serotype as used in the in vitro studies). In
this study, homozygous 3 ×TgAD mice expressing mu-
tant human genes APPswe, PS1M146V and tauP301L
(previously characterized by Oddo et al. [33]) and wild-
type mice from the same hybrid background strain, 129/
C57BL6, were used. Starting from 4 months of age,
3 ×TgAD mice received a daily intraperitoneal (i.p.) in-
jection of 50 mg/kg 3,6′-DT, Thal or vehicle (Solutol
(Sigma-Aldrich, St. Louis, MO,USA) in saline). Mice
were housed on a 12 h light and 12 h dark schedule. All
mice were given access to food and water ad libitum. At
6 months of age, the cognitive ability of the mice was
assessed. All procedures involving animals were
approved by the Institutional Animal Care and Use
Committee at the Veterans Administration-Greater Los
Angeles Healthcare System.
Radial arm maze
The RAM used in this study consists of eight equally
spaced arms radiating from a small circular central plat-
form. The arms were 35.0 cm in length, 5.0 cm in width
and 9 cm high (ANY-maze; Stoelting Co., Wood Dale,
IL, USA; Item 60150). The maze was elevated 94 cm
above the floor with each arm and the central platform
supported underneath by a small wood table. Extramaze
cues that surrounded the maze included the experi-
menter, two stainless steel racks, one wall-mounted stor-
age cabinet and a sink. The cues were kept in consistent
positions throughout the experiment and the maze was
uniformly lit from ceiling lighting.
Behavioral procedure
After mice were food-deprived to 90% of their ad libitum
body weight, behavioral training began. For the first
phase of behavioral training, mice were habituated to the
maze for seven consecutive days. During habituation,
three sucrose pellets (10 mg; P. J. Noyes Company, Inc.,
Lancaster, NH, USA) were placed down each of the eight
arms of the RAM. Mice were released to the center plat-
form and allowed to explore all eight arms, and arm
visits as well as sucrose pellet consumption were
recorded. Mice remained on the maze for 5 min during
each daily habituation trial. Mice that did not consume
any sucrose pellets or freely explore the maze by the end
of the habituation period were excluded from behavioral
testing.
After habituation was complete, the second phase of be-
havioral training began. Four arms were randomly selected
for each animal and baited at the far end of each arm. Mice
were released from the center platform, and arm visits were
recorded. The training trial was considered complete when
all four pellets were consumed or 5 min had passed. Two
types of errors were recorded; working memory errors were
revisits to arms that had been previously baited on the
same training trial, and reference memory errors were visits
to any of the four arms that had never been baited. In this
phase of training, mice were trained for 9 consecutive days.
The maze was wiped clean after each training trial
using paper towels that were dampened with water.
Tissue collection
Twenty-four hours after the last 3,6′-DT, Thal or vehicle in-
jection, animals were anesthetized with pentobarbital and
cardiac perfused with HEPES buffer (10mM HEPES,
137mM sodium chloride, 4.6mM potassium chloride,
1.1mM potassium phosphate monobasic, 0.6 mM magne-
sium sulfate and 1.1mM ethylenediaminetetraacetic acid)
containing sodium vanadate (1mM), sodium pyrophosphate
(1mM), sodium fluoride (50mM), leupeptin (0.002mM),
aprotinin (0.154μM), pepstatin (1.46μM) and phenylmethyl-
sulfonyl fluoride (287.36μM). The hippocampus and cortex
were dissected from one hemisphere and either snap-frozen
in liquid nitrogen (half cortex) and stored in a −80°C freezer
or stored at −20°C in RNAlater (Ambion Inc., Austin, TX,
USA) for PCR analysis. The contralateral hemisphere was
immersion fixed in formalin (Fisher Scientific, Pittsburgh,
PA, USA) for 24h followed by paraffin embedding.
Enzyme-linked immunosorbent assay
The levels of TNFα in culture media or mouse cortical or
spleen supernatants were measured using a commercially
available ELISA kit for mouse TNFα (BioLegend ELISA
MAX; BioLegend, San Diego, CA, USA) according to
manufacturer’s instructions. This kit detects optimally in
the 10 to 1,000 pg/mL range. Standards ranged from
7.8 pg/mL to 500 pg/mL in all assays. Samples were appro-
priately diluted to fall within the standard range and not
below.
In brief, 250 μL of tissue extraction reagent (Invitrogen,
Camarillo, CA, USA; Cat # FNN0071), containing protease
inhibitor cocktail (Sigma-Aldrich; Cat # P2714), was added
to each tissue sample. Tissue was homogenized with 20
passes of a Teflon pestle homogenizer. Homogenates were
centrifuged at 10,000 rpm for 10 min at 4°C and the result-
ing supernatants were removed and stored at −20°C until
use.
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Real time quantitative PCR analysis of tumor necrosis
factor-α gene expression
The samples were stored in RNAlater (Ambion Inc.) at
−20°C. Total RNA was extracted using TRI reagent
(Sigma-Aldrich) and BCP (Molecular Research Center,
Inc., Cincinnati, OH, USA) as a phase separation reagent.
RNA was purified using Qiagen’s RNeasy Kit (Qiagen,
Germantown, MD, USA) and was quantified spectro-
photometrically. RNA (1 μg) was reverse transcribed to
cDNA using RT2 First Strand Kit (Qiagen). Real time
quantitative (q)PCR, using an ABI 7300 Sequence Detec-
tion System (Applied Biosystems, Foster City, CA, USA),
was performed for quantification of low-density TNFα
mRNA. The amounts of mouse TNFα mRNA were
determined by amplification of the cDNA target using
the RT2 qPCR Primer Assay for TNFα (Qiagen). To
normalize the quantification of TNFα mRNA for pos-
sible differences in the amount of each cDNA template,
18 S rRNA served as a housekeeping gene. PCR amplifi-
cations of TNFα and 18 S rRNA genes were carried out
in conjunction with RT2 qPCR SYBR Green Master Mix
(Qiagen). Each cDNA sample was tested in triplicate.
The following temperature parameters were cycled 40
times: 15 s at 95°C, 1 min at 60°C. Standard curves were
constructed for 18 S rRNA as an internal standard and
for the TNFα gene. The amounts of TNFα mRNA gene
expression was normalized by division by the amount of
18 S rRNA mRNA in each sample and expressed as fold
change in comparison to control values.
Immunohistochemistry, thioflavin S and stereology
Formalin-fixed brains were embedded in paraffin and
35 μm thick coronal sections were mounted on glass
slides. Immunohistochemical staining for anti-ionized
calcium-binding adapter molecule 1 to identify microglia
(Iba-1, 1:800; Wako Chemicals, Neuss, Germany) or
monoclonal biotinylated 6E10 primary antibody (1:1000;
Covance, San Diego, CA, USA) for total APP/Aβ was
performed on these sections with the VectaStain Elite
ABC kit (Vector Laboratories, Burlingame, CA, USA).
Diaminobenzadine (Sigma-Aldrich) was used as the
chromagen. For 6E10, antigen retrieval using 70% formic
acid for 3 min was performed prior to antibody staining.
Design-based stereology was used to quantify Iba-1
and 6E10 positive cells in the hippocampus. We used the
optical fractionator method, a stereological method of
unbiased cell counting within a defined volume, using
Microbrightfield (MBF) Bioscience’s Stereo Investigator
software (Williston, VT, USA).. The optical fractionator
technique estimates the number of cells by multiplying
the sum of cells counted by the reciprocal of the fraction
of the region sampled. Briefly, sections were viewed with
a Nikon E600 microscope with a motorized stage, inter-
faced with a computer running Stereo Investigator 9.0.
The total hippocampus (Iba-1) and CA1 to CA2 region
(6E10) were identified on slide-mounted sections and
delineated for each section of each animal under a 2×
objective, based on the atlas of Franklin and Paxinos
[34]. Tissue thickness was measured at each sampling
site with a standard guard zone of 2 μm applied through-
out. Every fifth section was analyzed for a total of eight
sections per mouse, beginning at bregma −1.455 mm
and ending at −2.680 mm for Iba-1, and from bregma
−1.525 mm to −2.750 mm for 6E10. All sampling was
done under a 60× oil immersion objective. In addition to
6E10+ cell counts, 6E10 staining density in the CA1 to
CA2 region of the hippocampus was evaluated using
Image Pro Plus 5.0.1.11(Bethesda, MD, USA).
For thioflavin S, three sections (every fifth section begin-
ning at bregma −1.490 mm and ending at −1.840 mm) were
incubated for 8 min in an aqueous solution of thioflavin S
(1%w/v) and then differentiated twice with 80% ethanol for
3 min each, followed by another 3 min wash with 95% etha-
nol. Sections were rinsed three times with double distilled
water and coverslipped with Vectashield fluorescence
mounting medium (Vector Laboratories).
Flow cytometry
Flow cytometry was performed on a single cell suspen-
sion of brain-infiltrating leukocytes that were isolated
using a protocol based on the separation of microglia
and leukocytes by density centrifugation, as previously
described [35]. Briefly, following perfusion with ice- cold
1× Hank’s Balanced Salt Solution without phenol red to
remove blood, the brain (without cerebellum) was homo-
genized in Roswell Park Memorial Institute medium
using a dounce homogenizer with loose (pestle A) and
tight-fitting (pestle B) pestles and the cell suspension
layered over a discontinuous Percoll gradient. The cell
layer at the 70% to 30% Percoll interface was transferred
to a clean conical tube, diluted three times with
1 ×Hank’s Balanced Salt Solutionand centrifuged to pel-
let the cells. The pellet was re-suspended in 1 mL of cell
staining buffer in preparation for cell counting and flow
cytometry.
The fluorescent-conjugated flow anti-mouse Abs allo-
phycocyanin (APC)-conjugated anti-GR1 (RB6-8 C5) was
from BioLegend. Peridinin-chlorophyll-protein-complex
(PerCP)-conjugated anti-mouse CD45 (30-F11) was from
BD Biosciences. APC-Cy7conjugated anti-mouse LY6G
(1A8) and phycoerythrin (PE) -conjugated anti-mouse
TNFα (MP6-XT22) were purchased from eBiosciences
(San Diego, CA, USA). For flow cytometric evaluation,
leukocytic cell populations (approximately 106) were
stained in a volume of 50 μL of 2% FBS/PBS containing a
cocktail of three cell surface antibodies (anti-CD45, anti-
Gr1 and anti-LY6G) for 30 min on ice and then stained for
intracytoplasmic TNFα expression using BD Biosciences
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cytofix/cytoperm solution, according to the manufacturer’s
instructions. The stained cell samples were acquired on a
FACSScan or FACSCalibur flow cytometer (Becton Dick-
inson, San Jose, CA, USA) in the University of California,
Los Angeles, Jonsson Cancer Center Flow Cytometry Core
Facility. A total of 10,000 to 25,000 gated events were ana-
lyzed using FCS Express 3 (De Novo Software, Thornhill,
ON, Canada). Cells stained with irrelevant isotype-
matched antibodies and unstained cells served as controls.
The cutoffs were set according to control staining.
Statistical analysis
All data were normally distributed and are presented as
mean values ± standard error of the mean. In the case of
single mean comparisons, data were analyzed by un-
paired Student’s t -test. In the case of multiple mean
comparisons, the data were analyzed by one- or two-way
analysis of variance (ANOVA) followed by Bonferroni
multiple comparison tests using statistics software (Prism
5.0; GraphPad, LaJolla, CA, USA). P-values less than
0.05 were regarded to reflect a significant difference.
Results
Thalidomide and 3,6′-dithiothalidomide inhibit tumor
necrosis factor-α production induced by
lipopolysaccharide both in BV2 microglia cells in vitro and
brain cortical tissue in vivo
Initial studies were conducted in vitro to verify the effi-
cacy of Thal and 3,6′-DT (see Figure 1 for chemical
structures) to inhibit TNFα. BV2 microglial cell cultures
were treated with 1 ng/mL LPS with or without Thal or
3,6′-DT (1 and 10 μM). Culture media (n = 6 wells/treat-
ment) was collected 24 h later and evaluated for TNFα
protein levels via ELISA (Figure 2) and cytotoxicity by
measuring LDH release into the media. One-way
ANOVA revealed a significant effect of treatment
(F7,23 = 51.03; P< 0.0001). Both Thal and 3,6′-DT signifi-
cantly inhibited BV2 TNFα production at both concen-
trations compared with LPS alone (P< 0.0001 versus
both drugs, both doses). 3,6′-DT was a more potent in-
hibitor, with a half maximal inhibitory concentration
(IC50) value for TNFα inhibition of approximately 1 μM
while the IC50 value of Thal was in excess of 10 μM,
which is congruent with previous publications [36].
There was no increase in LDH in any treatment group
including DMSO alone, LPS alone, Thal or 3,6′-DT alone
or LPS plus Thal or 3,6′-DT (data not shown).
Both Thal and 3,6′-DT were effective at inhibiting
brain cortical TNFα mRNA and protein levels in a sys-
temic in vivo model of inflammation using LPS (Fig-
ure 3). C57 mice were given an i.p. injection of 100 mg/
kg Thal or 3,6′-DT 30 minutes prior to an i.p. 5 mg/kg
LPS injection. Four hours later, cortical tissue was har-
vested and analyzed by RT-PCR and ELISA. One-way
ANOVA showed a significant effect of treatment on
TNFα gene (F4,29 = 39.85; P< 0.0001) and protein
(F4,29 = 34.58; P< 0.0001) expression. Both Thal and
3,6′-DT reduced LPS-induced brain cortical TNFα
mRNA and protein levels to near vehicle-treated control
values (P< 0.0001).
Figure 1 The structures of thalidomide and 3,6′-dithiothalidomide.
Figure 2 Thalidomide and 3,6′-dithiothalidomide attenuate
lipopolysaccharide-induced increase in tumor necrosis factor-α.
BV2 cells were treated with 1 ng/mL LPS± Thal or 3,6′-DT for 24 h.
Initial studies in BV2 cells demonstrate that both Thal and 3,6′-DT are
effective at attenuating LPS-induced TNFα release into culture media.
3,6′-DT has an IC50 value of approximately 1 μM whereas the IC50 for
Thal is> 10 μM. n = 6 per group. One-way analysis of variance:
P< 0.0001; *P< 0.001 versus both drugs, both doses. LPS:
lipopolysaccharide; Thal: thalidomide; TNFα: tumor necrosis factor-α;
3,6′-DT: 3,6′-dithiothalidomide.
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3,6′-dithiothalidomide, but not thalidomide, prevents
cognitive impairment
Beginning at 4 month of age, 3 ×Tg mice were treated with
Thal, 3,6′-DT or vehicle for 2.5 months. There were no ob-
servable adverse effects of daily i.p. administration of Thal
or 3,6′-DT. Mice were habituated to the RAM and were
fully ambulatory and explored the RAM normally. Both
working and reference memory errors were quantified dur-
ing all acquisition sessions. Figure 4A,B represents the effect
of treatment on working memory errors and reference
memory errors made during the acquisition test, respect-
ively. Repeated measures ANOVA showed a statistical effect
of treatment on working memory errors (F3, 432 = 2.92,
P=0.042, Figure 4A) and a significant interaction of ‘treat-
ment by sessions’ (F24, 432 = 2.38, P=0.0003, Figure 4A). On
day 9, 3×Tg (vehicle) mice performed significantly worse
than Non-Tg mice (*P< 0.05, Bonferroni post hoc analysis),
and 3×Tg (3,6′-DT) mice performed significantly better
than 3×Tg (vehicle) mice (*P< 0.05), indicating that spatial
learning was impaired in vehicle-treated, but not impaired
in 3,6′-DT-treated 3×Tg mice. A similar statistical analysis
revealed that reference memory errors decreased with time
(F8, 432 = 0.53, P=0.6668, Figure 4B) but treatment did not
have a significant effect (F3, 432 = 260.4, P=0.6488,
Figure 4B). Figure 4 C indicates that there was no signifi-
cant difference in time to complete the RAM on day 9
(F 3,47 = 0.1635; P = 0.1635).
3,6′-dithiothalidomide treatment reduces brain and spleen
tumor necrosis factor-α levels
A significant reduction in brain TNFα gene expression
was observed in 3 ×Tg mice treated with 3,6′-DT but
not with Thal (Figure 5A; P= 0.033). There was a signifi-
cant effect of treatment on TNFα protein in the cortex
(ANOVA F3,35 = 4.956; P= 0.0062) with TNFα protein
significantly decreased to near Non-Tg levels by 3,6′-DT
(P< 0.05 3 ×Tg (vehicle) versus 3 ×Tg (3,6′-DT)) but
not by Thal treatment (Figure 5B). In contrast, both Thal
and 3,6′-DT were effective at reducing TNFα protein in
the periphery as assessed by 24-h splenocyte production
of TNFα (Figure 6). One-way ANOVA for treatment was
significant (F3,13 = 5.374; P= 0.0184) with P <0.05 for
3 ×Tg (vehicle) versus 3 ×Tg (3,6′-DT). The reduction
was not significant for 3 ×Tg (vehicle) versus 3 ×Tg
(Thal).
3,6′-dithiothalidomide improves the ratio of resting to
activated microglia
Using unbiased stereological methods, we examined
changes in Iba-1 positive microglia in the hippocampus
of 3 × Tg (vehicle, thalidomide- and 3,6′-DT-treated)
and Non-Tg mice (n = 3 to 4 per group) and found a sig-
nificant effect of treatment on total (F3,8 = 5.565;
P< 0.0233), activated (F3,8 = 20.88; P = 0.0004) and rest-
ing (F3,8 = 17.17; P = 0.0008) microglia (Figure 7). Treat-
ment of 3 × Tg mice with 3,6′-DT or Thal was effective
at reducing the total number of Iba-1 positive brain
microglia (Figure 7 Cc-Dd). Only 3,6′-DT increased the
ratio of resting microglia to activated microglia (as
assessed morphologically; see Figure 7, upper panel)
resulting in a microglial morphological profile in the
hippocampus that is more similar to the Non-Tg
hippocampus.
Amyloid precursor protein/amyloid beta peptide staining
is not changed by treatment with thalidomide or 3,6′-
dithiothalidomide
The number of 6E10+ cells in the CA1 to CA2 region of the
hippocampus was not changed by either Thal or 3,6′-DT
treatment. Intraneuronal 6E10 staining was light at
6.5 months of age in the 3×Tg mice with only an occasional
diffuse plaque found and the majority of the staining was
confined to cells in the hippocampus and cortex. Figure 8
shows representative sections of the CA1 to CA2 region of
Figure 3 3,6′-dithiothalidomide and thalidomide inhibited lipopolysaccharide-stimulated tumor necrosis factor-α gene and protein
expression in C57 mice. Mice were treated peripherally (intraperitoneal injection) with a single equivalent dose (100 mg/kg) of 3,6′-DT or Thal
30 min prior to a peripheral 5 mg/kg dose of LPS (intraperitoneal injection). Cortical tissue was harvested 4 hours after LPS injection. n = 6 per
group. One-way analysis of variance: P< 0.001; *P< 0.001 versus all other groups. LPS: lipopolysaccharide; Thal: thalidomide; TNFα: tumor necrosis
factor-α; 3,6′-DT: 3,6′-dithiothalidomide.
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the hippocampus. Stereological counts of CA1 to CA2 did
not reveal differences across treatment groups in either
numbers of 6E10+ cells in this region or in 6E10 optical
density. At 6.5 months of age, thioflavin S+deposits were
not seen in the 3×Tg mouse model [37] and none were
observed in 6.5 month control 3×Tg mice in this study.
Treatment with Thal or 3,6′-DT did not alter this.
3,6′-dithiothalidomide reduces tumor necrosis factor-α in
central nervous system-infiltrating leukocytes
Infiltrating leukocytes were isolated from whole brains to
determine if treatment could alter the numbers of periph-
erally infiltrating cells (Figure 9; ANOVA F3,11 = 85.19; P
< 0.0001). 3 ×Tg mice have greater than twice the num-
bers of infiltrating leukocytes as Non-Tg mice (P< 0.001).
These infiltrates were derived from whole brain homoge-
nates and it is unknown to what extent these leukocytes
migrated into the brain parenchyma or if they were
maintained in the perivascular compartments of the brain.
Both Thal and 3,6′-DT reduced the numbers of
these cells (P< 0.0001 versus 3×Tg (vehicle)). 3,6′-DT
was more effective than Thal at reducing the numbers
of infiltrating leukocytes (P< 0.001; 3 ×Tg (3,6′-DT) ver-
sus 3×Tg (Thal)), reducing the numbers well below Non-
Tg cell numbers (P< 0.001; 3 ×Tg (3,6′-DT) versus Non-
Tg).
Figure 4 3,6′-dithiothalidomide improves cognitive performance as assessed using the eight-arm radial arm maze in 3× Tg mice. (A)
6.5-month-old 3 × Tg mice demonstrate a significant working memory deficit relative to age-matched Non-Tg mice (n = 15). Daily intraperitoneal
administration of 50 mg/kg, 3,6′-DT for 2.5 months (4 to 6.5 months of age) significantly improved working memory errors (WME) in 3 × Tg mice
(n = 11) compared with vehicle-treated (n = 14) or Thal-treated (50 mg/kg intraperitoneal injection; n = 11) 3 × Tg mice. No difference in WME was
observed between 3, 6′-DT-treated 3 × Tg mice and age-matched Non-Tg mice. One-way analysis of variance: P= 0.0076. *P< 0.05. (B) Reference
memory errors and (C) time to complete the radial arm maze on the last day of testing were not significantly different between groups. Thal:
thalidomide; TNFα: tumor necrosis factor-α; 3,6′-DT: 3,6’-dithiothalidomide; WME: working memory errors.
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3,6′-dithiothalidomide decreased tumor necrosis factor-α
in myelomonocytic/granulocytic cells
CNS-infiltrating leukocytes were isolated and stained for
fluorescence activated cell sorting (FACS) analysis to
evaluate the changes in the CD45hi population and their
TNFα expression (Figure 10 and Table 1). There was a
trend towards increased percentage of CD45hi (ANOVA;
P=0.16) and CD45hi/Gr1
+/Ly6Ghi (myelomonocytic/gran-
ulocytic; ANOVA P=0.10) populations in the 3 ×Tg rela-
tive to Non-Tg mice. TNFα production was increased in
both the CD45hi and the CD45hi/Gr1
+/Ly6Ghi populations
in the 3 ×Tg mice relative to Non-Tg mice. 3,6′-DT




There is a robust increase in TNFα expression levels in
the CNS during numerous experimental models of both
acute injury and chronic neurodegenerative disease, such
as AD, suggesting a significant role for this cytokine in
the injury or disease process [12,38]. Neuroinflammation
begins early in AD and accompanies Aβ accumulation
and neurodegeneration [39]. Still nebulous is whether
this AD-related inflammatory response is advantageous
or deleterious and what the best approach is to resolving
the inflammatory tide while simultaneously allowing
beneficial processes to continue. In the current study, we
focus on the central role of TNFα and its modulation in
inflammatory regulation and cognitive function in the
3 ×Tg mouse model of AD.
Although there is ample evidence that TNFα plays a
central role in brain development and homeostatic and
repair mechanisms [40], many studies demonstrate a
negative role for TNFα in AD pathology. APP/presenilin
1 (PS1) transgenic mice receiving short-term CNS infu-
sion of anti-TNFα monoclonal antibody showed reduced
Figure 5 Tumor necrosis factor-α gene and protein expression in the 3× Tg mouse. (A) Fold-change (2^(− δ δCt)) is the normalized gene
expression (2^(−δ Ct)) in the test sample (3 × Tg treated with Thal or 3,6′-DT) divided by the normalized gene expression (2^(−δ Ct)) in the
control sample (vehicle-treated 3 × Tg). Fold-change values of less than one indicate a negative- or downregulation. Both Thal and 3,6′-DT
downregulated TNFα gene expression but the value was significant only in the 3,6′-DT group (P= 0.033). (B) TNFα protein levels are doubled in
the cortex of 3 × Tg mice compared with Non-Tg mice. 3,6′-DT, but not Thal, reduced TNFα protein levels near to Non-Tg levels in 3 × Tg mice.
n = 5 to 8 per group. One-way analysis of variance (P= 0.062, *P< 0.05). Thal: thalidomide; TNFα: tumor necrosis factor-α; 3,6′-DT:
3,6’-dithiothalidomide.
Figure 6 Tumor necrosis factor-α protein from splenocytes
isolated from Non-Tg and 3× Tg mice. Splenocytes isolated from
Non-Tg and 3 × Tg mice were cultured for 24 hours and TNFα levels
measured by ELISA. 3,6′-DT-treated 3 × Tg mice had significantly
reduced TNFα secretion compared with vehicle-treated 3 × Tg mice.
One-way analysis of variance: P= 0.0184. *P< 0.05 versus 3 × Tg
(vehicle). ELISA: enzyme-linked immunosorbent assay; 3,6′-DT: 3,6′-
dithiothalidomide; Thal: thalidomide; TNFα: tumor necrosis factor-α.
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tau pathology and amyloid plaque deposits [41]. Ligation
of microglial CD40 with its cognate ligand, CD40 ligand
(CD40L, expressed by activated astrocytes associated
with beta-amyloid plaques [42]), synergistically activated
microglia to produce TNFα in response to low levels of
Aβ peptides. This form of microglial activation was dele-
terious, as it resulted in TNFα-dependent neuronal in-
jury. Further, when mice deficient in CD40L were
crossed with the Tg2576 mouse model of AD, abnormal
phosphorylation of tau (an index of neuronal stress) was
Figure 7 Stereological analysis of ionized calcium-binding adapter molecule 1 staining in the hippocampus. Unbiased stereological
methods were used to analyze 35 μm sections, every fifth section through the hippocampus (total of eight sections per mouse; n = 3 to 4 per
group). The top panel shows the morphological criteria used for designating resting versus activated Iba-1 positive microglia. Middle Panel: (Aa)
Non-Tg; (Bb) 3 × Tg (vehicle); (Cc) 3 × Tg (Thal); (Dd) 3 × Tg (3,6′-DT) mice. Bottom panel: total, resting and activated cell counts. Bonferroni post
hoc testing: *P< 0.05, **P< 0.01, ***P< 0.001. Bar equals 40 μm (A), 10 μm (a). 3,6′-DT: 3,6′-dithiothalidomide; Iba-1: ionized calcium-binding
adapter molecule 1; Thal: thalidomide.
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reduced prior to beta-amyloid deposition, suggesting that
the CD40-CD40L interaction is an early event in AD
pathogenesis [43]. However, complete abrogation of
TNFα is not beneficial in the context of AD. Giuliani
and coworkers used the PDAPP mouse model to demon-
strate increased amyloid plaque burden and no cognitive
improvement following chronic TNFα ablation [44]. The
dual mission of TNFα may depend on the timing and
progression of damage. In a model of traumatic brain in-
jury, TNFα-null mice exhibited less severe cognitive and
motor neuron impairments than wild type (WT) mice in
the acute post-traumatic period [45]. While neurological
functions recovered by 2 to 3 weeks post-injury in WT
mice, TNFα-null animals still demonstrated motor defi-
cits at 4 weeks and brain damage was significantly more
extensive in TNFα-deficient mice. What remains unclear
after these important studies is which approach to pur-
sue in balancing the dual roles of the inflammatory re-
sponse in AD. Our data indicate that long-term
modulation with the small molecule TNFα inhibitor
3,6′-DT is safe, reduces CNS TNFα levels and improves
cognitive function in the early stages of disease in the
3 ×Tg mouse. It will be important to assess long-term
dosing strategies that encompass later disease stages for
safety and impact on the development of the classical
neuropathological features of AD, such as tau pathology
(not seen at the age of the mice in this study; see
[33,37]) and amyloid accumulation. It is important to
note that, at this early phase of the disease, treatment of
3 ×Tg mice with either Thal or 3,6′-DT did not increase
intraneuronal Aβ or Aβ plaque deposition.
TNFα has already been validated as a drug target with
infliximab (Remicade), etanercept (Enbrel) and
Figure 8 Amyloid precursor protein/amyloid beta peptide staining is not changed in 3× Tg mice by 3,6′-dithiothalidomide or
thalidomide treatment. 6E10 immunohistochemistry was stereologically analyzed in the hippocampal CA1 to CA2 regions (left graph; n = 5 to 6
mice per treatment). There were no statistically significant differences in 6E10+ cell counts between treatment groups. Representative
photomicrographs of each treatment group are shown. The same regions were also analyzed for optical density (right graph) and show that there
were no differences between treatment groups.
Figure 9 3,6′-dithiothalidomide reduces central nervous system-
infiltrating peripheral blood leukocytes. Mononuclear cells were
isolated from the whole brains of Non-Tg and 3× Tg mice (vehicle-,
Thal- and 3,6′-DT-treated; n = 3 to 4 per group) following 2.5 months
of treatment and counted using a hemocytometer. One-way analysis
of variance: P< 0.0001; *P< 0.001 versus Non-Tg, **P< 0.001 versus
3 × Tg (Thal). Thal: thalidomide; 3,6′-DT: 3,6’-dithiothalidomide.
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adalimumab (Humira) in clinical use. Short-term, extra-
thecal etanercept administration in patients with AD
achieved significant cognitive and behavioral improve-
ments [46-48]. As AD treatment necessitates chronic,
long-term treatment, perispinal injections are neither
practical nor safe in this context and the development of
small, drug-like molecules to potently and safely inhibit
TNFα is of significant clinical value. Thalidomide, a
small molecule glutamic acid derivative demonstrating
anti-TNFα actions, enhances the degradation of TNFα
mRNA [49-51]. Recent preclinical studies indicate the
therapeutic potential of employing thalidomide as an AD
Figure 10 3,6′-dithiothalidomide reduces tumor necrosis factor-α in central nervous system-infiltrating myelomonocytic/granulocytic
leukocytes. (A) Non-Tg mice; (B) 3 × Tg mice; (C) 3,6′-DT mice. CNS-infiltrating leukocytes from whole mouse brains (n = 3 to 4 per group) were
isolated and evaluated for the presence of CD45hi and myelomonocytes/granulocytes (CD45hi/Gr1
+/Ly6Ghi) by cell surface staining and flow
cytometric analyses. There was a trend towards an increased percentage of CD45hi cells and CD45hi/Gr1
+/Ly6Ghi (not significant) in 3 × Tg mice (B)
relative to Non-Tg (A) mice. 3,6′-DT (C) did not alter the percentages of these cell populations. TNFα expression in the total CD45hi population and
in the granulocyte population was increased in 3 × Tg mice relative to Non-Tg mice. 3,6′-DT treatment did not reduce TNFα expression in the
total CD45 hi population but specifically reduced TNFα expression in the CD45hi/Gr1+/Ly6Ghi population (P= 0.031). Flow cytometry results were
quantified and are presented in Table 1.
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treatment. Daily treatment with thalidomide (20 mg/kg)
improved recognition memory induced by Aβ(25–35) or
Aβ(1–40) in mice [52]. These data suggest the practic-
ability of small molecules that target TNFα as a thera-
peutic strategy against Aβ-mediated cognitive
impairments. However, thalidomide’s use in humans is se-
verely restricted by its well-documented side effects, such
as somnolence, deep-vein thrombosis and peripheral
neurotoxicity [53]. Thalidomide also has a high IC50 for
TNFα inhibition, necessitating chronic high dosing to
achieve significant clinical benefit while increasing risk for
side effects in patients with AD.
In this report, a novel experimental TNFα synthesis in-
hibitor, 3,6′-DT [54,55], a lipophilic analog of the classic
orally active thalidomide, was evaluated. 3,6′-DT was
shown to be effective in ameliorating the TNFα increase
and cognitive impairment resulting from a mild traumatic
brain injury in mice [36]. In the current study, 3,6′-DT
and thalidomide were equally effective, at a high dose, in
preventing CNS TNFα increases resulting from LPS-
induced systemic inflammation in WT mice. However,
only 3,6′-DT was effective at lowering TNFα in the CNS
of 3×Tg mice and improving cognitive function. The lack
of efficacy by thalidomide in the 3 ×Tg model may be due
to a higher IC50 value than 3,6′-DT or a difference in brain
penetrance. 3,6′-DT has an assessed brain to plasma ratio
of 1.34 [36], which is in accord with its partition coefficient
(cLogD) value of −0.56 [54,55], a measure of its balanced
aqueous solubility and lipophilicity. Thalidomide has a
moderate degree of lipophilicity with a cLogD value of
−0.83 [56]. Further, thalidomide has demonstrated poor
ability in vitro to reduce LPS-stimulated TNFα while sig-
nificantly increasing toxic nitrite levels [36].
Within the CNS, the main executors of innate immunity
are perivascular macrophages and parenchymal microglia
[57]. Resting microglia are highly ramified with branched
processes and have critical physiologic roles, including
determination of neuronal fate, migration, axonal growth
and synaptic remodeling [58,59]. In response to patho-
logical conditions, microglia transform into a reactive state
[58,60,61], losing their ramified morphology and switching
from a neurotrophic phenotype to a persistent, reactive
phenotype expressing toxic and reparative functions [59].
Inflammation clearly occurs in pathologically vulnerable
regions of the AD brain [62,63], and both animal models
and clinical studies strongly suggest that inflammation sig-
nificantly contributes to AD pathogenesis [39]. 3 ×Tg mice
showed a large increase in Iba-1 positive microglia at
6.5 months of age compared with Non-Tg mice and the
majority of these microglia had an activated morphology.
Although both thalidomide and 3,6′-DT reduced the total
numbers of Iba-1 positive microglia, only 3,6′-DT
improved the ratio of resting to activated microglia and
created a microglial morphological profile that was nearly
identical to that of the Non-Tg brain. 3 ×Tg mice treated
with thalidomide had predominately activated Iba-1 posi-
tive microglia.
Although considerable focus has been given to the CNS-
endogenous innate immune system, the CNS-endogenous
and peripheral immune systems do not function in isola-
tion from each other and there is dynamic interplay. In the
healthy brain, peripheral immune cells are indispensable
for homeostasis whereas specific cell types play different
roles in neuroprotection and neurodestruction [64]. This
activity must be tightly regulated or the immune system
will become hyperactivated, leading to dysregulation and
pathological sequelae. One of the many known functions
of TNFα is to stimulate the recruitment of innate effectors
such as neutrophils/granulocytes and monocytes and to
activate these cells in a paracrine manner. After being acti-
vated by injury or disease, innate immune system func-
tions focus on the clearance of pathogens and debris,
tissue repair and in orchestrating adaptive immune
responses [58,65,66].
While the inflammation within the AD brain has been
assumed to be a locally-mediated inflammatory response
by microglia to Aβ [39], systemic immune responses may
also play a role. Prior to entering the CNS, leukocytes
encounter formidable barriers to access including the
endothelial blood–brain barrier, the epithelial blood-CSF
barrier and the tanycyte barrier surrounding the circum-
ventricular organs [67]. The mechanisms by which leu-
kocytes infiltrate the healthy brain during adulthood and
aging are not clear [68], but there is strong evidence that
a compromised blood–brain barrier in brain diseases,
such as stroke or brain trauma [69], and AD [70-75]
allows leakage of leukocytes into the brain. TNFα can
cause vascular endothelial damage and an increase in
vascular endothelial permeability [76]. In regards to
macrophage infiltration into the CNS, there are no spe-
cific immunohistochemical markers to distinguish blood-
derived macrophages from brain endogenous microglial
cells, making the distinction difficult. Recent human
studies demonstrate that recruited monocytic cells






Non-Tg 6.7 ± 1.8 5.5 ± 2.0 - -
3×Tg 14.3 ± 4.9 13.9 ± 4.4 493 ± 197.7 88.5 ± 16.7
3×Tg
(3,6′-DT)
17.4 ± 1.9 13.6 ± 1.3 759 ± 75.3 28.3 ± 5.2
P n.s. n.s. n.s. 0.0309
aTNFα is expressed as a percentage increase from Non-Tg values. P-value is
3 × Tg versus 3 × Tg (3,6′-dithiothalidomide). Results are expressed as the
mean ± standard error; n = 3 to 4 mice per group. n.s.: not significant; TNFα:
tumor necrosis factor-α.
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express markers for microglia yet are morphologically
and functionally separate from the resident microglia in
the AD brain [71-75]. Contradicting the importance of
leukocytes in AD pathology, histological examination of
postmortem AD brains has not demonstrated abundant
leukocytic infiltrates. Future studies and more sophisti-
cated methodologies are required to determine if this is
a disease stage phenomenon and what contributions in-
filtrating leukocytes may make to early stage AD and
progression of the disease. In this regard, animal models
of AD are valuable.
Recent studies in AD animal model pathology have ele-
gantly examined the important role that brain-infiltrating
monocytes play in Aβ clearance. Angelucci et al. crossed
an AD mouse model with an animal deficient in CC-che-
mokine receptor 2 [77]. These bigenic mice have markedly
diminished recruitment of brain resident microglia and/or
peripheral macrophages to sites of beta-amyloid plaques
and demonstrate heavier Aβ protein burden than AD
model mice alone. While this study does not definitively
establish the provenance of the amyloid clearing cells, it
demonstrates the importance of brain innate immunity in
restricting cerebral amyloidosis. An additional report has
shown that depletion of CD11c+ cells using a CD11c-diph-
theria toxin transgenic mouse bone marrow chimera in an
AD mouse model opposes the beneficial effect of T cell-
directed immunotherapy, suggesting that peripheral innate
immune cells are required for Aβ clearance [78]. These
studies, by negatively impacting brain penetration and Aβ
homing of these peripheral innate immune cells, lead to
the deduction that such cells are critical for reducing amyl-
oid accumulation. However, if these cells are to be targeted
as a therapeutic modality, strategies for selectively increas-
ing brain leukocyte infiltration and increasing Aβ clearance
potential need to be developed. A recent study demon-
strated that blood-borne monocytes can be encouraged to
enter the brain and restrict Aβ plaques without producing
a potentially damaging neuroinflammatory response [79].
Previous work [80] and the current study demonstrate
that the 3×Tg mouse has a robust increase in CNS
leukocyte infiltrates early in the disease process, and that
intracellular TNFα levels in this population are greatly
increased relative to Non-Tg mice. Both thalidomide and
3,6′-DT reduced the total numbers of infiltrating periph-
eral leukocytes in the CNS of 3×Tg mice as measured by
flow cytometry but 3,6′-DT effected a striking reduction.
The similar parallel finding of reduced Iba-1 microglia fol-
lowing thalidomide or 3,6′-DT treatment suggest that
reducing the infiltrating leukocyte population contributed
to the reduction in Iba-1 positive microglia. Additionally,
only 3,6′-DT improved the resting to activated ratio of
CNS microglia suggesting that the improved CNS pene-
trance and lower IC50 of 3,6′-DT compared with thalido-
mide is necessary for efficacy.
3,6′-DT did not, however, change the percentages of
specific cell types within the total leukocytic population
or alter TNFα levels in the total CD45hi population.
Rather, 3,6′-DT specifically reduced intracellular TNFα
levels in the CD45hi/GR1
+/Ly6Ghi (granulocytic) subpo-
pulation. Due to a paucity of studies, it is unclear what
the role of granulocytes is in the human AD brain, par-
ticularly in the early stages of the disease, and further
studies are needed to determine if granulocytes migrate
through the brain parenchyma or are involved in inflam-
matory signal transduction from the perivascular regions
of the brain. Regardless, these data raise interesting ques-
tions about AD immunotherapy and suggests that, in
addition to reducing the total number of infiltrating leu-
kocytes, modulation of TNFα by small molecule TNFα
inhibitors, in specific subsets of peripheral leukocytes,
may be therapeutic.
Chronic neuroinflammation is an important component
of AD pathogenesis and undoubtedly contributes to neur-
onal dysfunction, injury, loss and disease progression. A
recent proteomic profiling study examined the CSF of
young individuals who will go on to develop familial AD
in comparison with age-matched controls not carrying a
familial AD mutation [81]. The study noted increases in
multiple complement cascade components as much as a
decade prior to the onset of overt AD symptomology, indi-
cating that neuroinflammation plays a very early role in
the disease process. These and other data underscore the
therapeutic potential of targeted anti-inflammatory phar-
maceuticals both early and throughout the course of the
disease. Unfortunately, our knowledge of CNS-related im-
mune function is currently limited and the study of the
interface between the peripheral and CNS-endogenous
immune systems is in its infancy. Understanding the mo-
lecular manipulations required to produce beneficial
changes in leukocyte and microglial activation profiles is
necessary to beget more sophisticated immunomodulatory
strategies for the treatment of AD.
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